scholarly journals Stimuli-responsive drug delivery systems for head and neck cancer therapy

Drug Delivery ◽  
2021 ◽  
Vol 28 (1) ◽  
pp. 272-284
Author(s):  
Jingou Liang ◽  
Bina Yang ◽  
Xuedong Zhou ◽  
Qi Han ◽  
Jing Zou ◽  
...  
Author(s):  
Sauraj ◽  
Anuj Kumar ◽  
Bijender Kumar ◽  
Ruchir Priyadarshi ◽  
Chhavi Sharma ◽  
...  

2021 ◽  
Vol Volume 16 ◽  
pp. 1525-1551
Author(s):  
Ruixin Jia ◽  
Lesheng Teng ◽  
Lingyu Gao ◽  
Ting Su ◽  
Lu Fu ◽  
...  

2021 ◽  
Vol 10 (1) ◽  
pp. 933-953
Author(s):  
Baranya Murugan ◽  
Suresh Sagadevan ◽  
Is Fatimah ◽  
Won-Chun Oh ◽  
Mohd Abd Motalib Hossain ◽  
...  

Abstract Nanomedicine is ongoing current research in the applications of nanotechnology for cancer therapy. Simply from a technology perspective, this field of research has an enormous broadening and success to date. Recently, nanomedicine has also made inroads in the treatment of cancer. Stimuli-responsive nanoparticles are an emerging field of research because its targeting capacity is of great interest in the treatment of cancer. The responsive nanoparticles are efficient in encountering different internal biological stimuli (acidic, pH, redox, and enzyme) and external stimuli (temperature, ultrasounds, magnetic field, and light), which are used as smart nanocarriers for delivery of the chemotherapeutic and imaging agents for cancer therapy. In-depth, the responsive nanocarrier that responds to the biological cues is of pronounced interest due to its capability to provide a controlled release profile at the tumor-specific site. The outlook of this review focuses on the stimuli-responsive nanocarrier drug delivery systems in sequence to address the biological challenges that need to be evaluated to overcome conventional cancer therapy.


2020 ◽  
Vol 21 (11) ◽  
pp. 1084-1098
Author(s):  
Fengqian Chen ◽  
Yunzhen Shi ◽  
Jinming Zhang ◽  
Qi Liu

This review summarizes the epigenetic mechanisms of deoxyribonucleic acid (DNA) methylation, histone modifications in cancer and the epigenetic modifications in cancer therapy. Due to their undesired side effects, the use of epigenetic drugs as chemo-drugs in cancer therapies is limited. The drug delivery system opens a door for minimizing these side effects and achieving greater therapeutic benefits. The limitations of current epigenetic therapies in clinical cancer treatment and the advantages of using drug delivery systems for epigenetic agents are also discussed. Combining drug delivery systems with epigenetic therapy is a promising approach to reaching a high therapeutic index and minimizing the side effects.


Sign in / Sign up

Export Citation Format

Share Document